Home › Applications › Liquid Biopsy

Application

Liquid Biopsy with FLA

Towards a blood test for the early detection of pancreatic cancer.

Pancreatic ductal adenocarcinoma has a five-year survival rate below 10%, largely because it is detected late, and no adequate screening programme exists today.

In a non-invasive liquid biopsy, nanoparticles in contact with a blood sample become coated with disease-specific markers. Their fluorescence lifetime fingerprint, read by fluorescence lifetime analysis (FLA), can reveal signs of cancer.

Nanoparticles are added to a patient blood sample and become coated with molecules from it. Fluorescence lifetime analysis of the coated nanoparticles gives a fingerprint that differs between healthy donors and cancer patients. Schematic.

01 EIC Pathfinder project

Biophotonic nanoparticle-enabled laser blood test for early detection of pancreatic cancer. Coordinated by FLIM LABS, the project aims to develop an in vitro diagnostic test for mass screening and reduce the mortality of this cancer by 80%.

Funded by the European Innovation Council through the Horizon Europe Pathfinder programme, grant agreement No. 101130740.

02 Solutions

FLIM LABS solutions for liquid biopsy

FLIM LABS components and software cover the measurement chain shown above: pulsed excitation of the coated nanoparticles, single-photon detection with TCSPC acquisition, and phasor analysis of the measured lifetimes.

Spectroscopy

FLIM LABS Spectroscopy

Discover

Acquisition

FLIM DAQ

Discover

Excitation

Pulsed Laser Diodes

Discover

Get started

Read the lifetime fingerprint of your samples

Tell us about your nanoparticles and blood-derived samples and we will help you set up pulsed excitation, single-photon detection and phasor analysis for fluorescence lifetime analysis.